[go: up one dir, main page]

NO934776L - Rensing av rekombinant apoliproteiner E fra bakterier - Google Patents

Rensing av rekombinant apoliproteiner E fra bakterier

Info

Publication number
NO934776L
NO934776L NO934776A NO934776A NO934776L NO 934776 L NO934776 L NO 934776L NO 934776 A NO934776 A NO 934776A NO 934776 A NO934776 A NO 934776A NO 934776 L NO934776 L NO 934776L
Authority
NO
Norway
Prior art keywords
apoe
purification
recombinant
analog
fatty acids
Prior art date
Application number
NO934776A
Other languages
English (en)
Other versions
NO934776D0 (no
Inventor
Ruth Lifshitz
Meir Fischer
Benjamin Greenman
Daniel Bartfeld
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NZ238813A external-priority patent/NZ238813A/en
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Publication of NO934776D0 publication Critical patent/NO934776D0/no
Publication of NO934776L publication Critical patent/NO934776L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Fremgangsmåter for rensing av humant ApoE eller analog derav fra rekomblnante bakterielle celler med minimal protein aggregasjon og degradering i løpet av rens- ningsprosessen er beskrevet. Tilsetning av nøytrali- serende fettsyrer til mediet l løpet av celle- ødeleggelsen og anvendelse av en ikke-ionisk detergent iløpet av rensningsprosessen er beskrevet. Videre er en fremgangsmåte for å øke produksjonen av ApoE eller analog derav i en bakteriell vert ved tilsetning til dyrkningsmediet næytraliserende fettsyrer, fettsyre- forløpere, triglycerider, triglyceridforløpere eller acetat samt farmasøytiske og diagnostiske anvendelser av ApoE analogen, er beskrevet.
NO934776A 1991-06-26 1993-12-22 Rensing av rekombinant apoliproteiner E fra bakterier NO934776L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1991/004553 WO1993000443A1 (en) 1991-06-26 1991-06-26 Purification of recombinant apolipoprotein e from bacteria
NZ238813A NZ238813A (en) 1991-06-26 1991-07-01 Production and purification of apolipoprotein e (apo e) and its use
US08/333,872 US5525472A (en) 1991-06-26 1994-11-03 Method for production and purification or recombinant Apolipoprotein E from bacteria

Publications (2)

Publication Number Publication Date
NO934776D0 NO934776D0 (no) 1993-12-22
NO934776L true NO934776L (no) 1994-02-17

Family

ID=27353645

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934776A NO934776L (no) 1991-06-26 1993-12-22 Rensing av rekombinant apoliproteiner E fra bakterier

Country Status (3)

Country Link
US (1) US5525472A (no)
NO (1) NO934776L (no)
WO (1) WO1993000443A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7526494A (en) * 1993-08-12 1995-03-14 Bio-Technology General Corporation Method of inhibiting kaposi's sarcoma
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6277874B1 (en) * 1996-07-09 2001-08-21 University Of Cincinnati And Apologic, Incorporated Methods for the treatment of apolipoprotein E related diseases
CA2277199A1 (en) * 1996-09-11 1998-03-19 Hans Ageland A process for purifying apolipoproteins and a composition for use in the process
DK0954524T3 (da) * 1996-09-11 2003-08-04 Pharmacia Ab Fremgangsmåde til rensning af apolipoproteiner
DE60103137T2 (de) * 2000-03-03 2005-05-25 Glaxosmithkline Biologicals S.A. Impstoff zur behandlung von atherosclerosis
US6555391B1 (en) * 2000-08-15 2003-04-29 Baxter International, Inc. Methods of conditioning an affinity resin after storage
AU2002213843B2 (en) * 2000-11-10 2008-02-07 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
CN1312273C (zh) * 2002-09-30 2007-04-25 中国科学院沈阳应用生态研究所 一种光合细菌培养基用添加剂
DE10309691B4 (de) * 2003-02-28 2018-10-04 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Gewinnung von löslichen Proteinen aus der Biomasse rekombinanter Mikroorganismen
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
CN100586958C (zh) * 2006-12-20 2010-02-03 上海莱士血液制品股份有限公司 高纯度载脂蛋白a-i的制备方法
US8013122B2 (en) * 2006-12-20 2011-09-06 Kieu Hoang Method of purifying apolipoprotein A-1
US8324366B2 (en) * 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
CA2743136C (en) 2008-11-10 2019-02-26 Muthiah Manoharan Novel lipids and compositions for the delivery of therapeutics
CA3036963A1 (en) 2009-01-29 2010-08-05 Arbutus Biopharma Corporation Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
CA3151387A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
US9029338B2 (en) 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120245076A1 (en) * 2009-09-03 2012-09-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering rnai using apoe
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US9012498B2 (en) 2010-06-03 2015-04-21 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
DK2663548T3 (en) 2011-01-11 2017-07-24 Alnylam Pharmaceuticals Inc PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
ES2717455T3 (es) 2011-02-07 2019-06-21 Cerenis Therapeutics Holding Sa Complejos de lipoproteínas y fabricación y usos de los mismos
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4656132A (en) * 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
US4943527A (en) * 1985-10-04 1990-07-24 California Biotechnology Inc. Mature apoai protein production under serum free culturing conditions
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum

Also Published As

Publication number Publication date
NO934776D0 (no) 1993-12-22
WO1993000443A1 (en) 1993-01-07
US5525472A (en) 1996-06-11

Similar Documents

Publication Publication Date Title
NO934776L (no) Rensing av rekombinant apoliproteiner E fra bakterier
DE3152001C2 (no)
LU91704I2 (fr) Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®)
ATE188255T1 (de) Von blutplättchen abstammende biologisch aktive analoga eines wachstumsfaktors in eukaryotischen zellen
ES8602112A1 (es) Procedimiento para preparar un polipeptido ciclico
DE69736391D1 (de) Verfahren zur herstellung eines rekombinanten polypeptids unter hinzufügung eines hemmstoffes einer metallabhängigen protease oder chymotrypsins zum zellkulturmedium
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
ATE60362T1 (de) Verfahren zur herstellung von oligosaccharide enthaltenden produkten aus biomassen, diese oligosaccharide enthaltenden produkte und ihre verwendung.
ATE42106T1 (de) Verfahren zur herstellung von estern von nichtreduzierendem zucker oder zuckeralkohol und einer oder mehreren fettsaeuren.
DE69109298D1 (de) Verfahren zur modifizierung von zell-, gewebe- oder wirts-tropismus eines mikroorganismus, so erhaltene rekombinante mikroorganismen sowie deren verwendung in medizin und tiermedizin.
KR910012226A (ko) 핵산의 생물학적 불활성화 방법
DE3880380D1 (de) Fermentative herstellung von dicarbonsaeuren.
DE68928634D1 (de) Verfahren zur Herstellung von aktivierten Killer-Monozyten und Verfahren zur Überprüfung ihrer tumoriziden Aktivität
Foster et al. Improved methodologies for the isolation and purification of tropoelastin
FR2546905B1 (fr) Procede de prevention et traitement des arrets de fermentation en vinification
Belkoura et al. Effect of environmental conditions on the fatty acid composition of the green alga Chlorella sorokiniana SHIKIRA et KRAUSS
DE2418716C3 (de) Verfahren zur Reinigung von Pilzalpha-Amylase
DE60128927T2 (de) Stereoselektive esterase aus aspergillus oryzae
CN119320426A (zh) 一种具有促进皮肤修复作用的抗炎活性肽及其应用
RU93017054A (ru) Способ переработки пищевых отходов
JPS5876085A (ja) 地衣植物組織培養方法
JPS5618591A (en) Production of substance capable of differentiation and multiplication of stem cells of human granulocyte
이원호 Applied Researches on Microalgae (Overview)
JPS63146788A (ja) ペプチダ−ゼ及びその製造方法
DE2304846A1 (de) Verfahren zur anreicherung und reinigung von l-lysinoxygenase, sowie ihre verwendung als arzneimittel